

Zilretta (triamcinolone extended-release)
Effective 06/01/2025

Plan	<input checked="" type="checkbox"/> MassHealth <input type="checkbox"/> Commercial/Exchange		Program Type	<input checked="" type="checkbox"/> Prior Authorization
Benefit	<input type="checkbox"/> Pharmacy Benefit <input checked="" type="checkbox"/> Medical Benefit			<input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Specialty Limitations	N/A			
Contact Information	Medical Benefit	Phone: 833-895-2611	Fax: 888-656-6671	
	Pharmacy Benefit	Phone: 800-711-4555	Fax: 844-403-1029	
Exceptions	N/A			

Overview

Zilretta (triamcinolone extended-release) is an intra-articular corticosteroid injection indicated for the management of osteoarthritis pain of the knee.

Coverage Guidelines

Authorization may be granted for members when all the following criteria are met, and documentation is provided:

1. Diagnosis of osteoarthritis pain of the knee
2. Physician attestation of inadequate response or adverse reaction to **TWO** different intra-articular corticosteroid injection preparations or contraindication to **ALL** other intra-articular corticosteroid injection preparations
3. Appropriate dosing

Limitations

1. Initial approvals will be granted for 1 month (30 days)
2. Zilretta is not intended for repeat administration

References

1. Zilretta® [package insert]. San Diego(CA): Pacira Pharmaceuticals, Inc; 2025 Jan.
2. Micromedex®Healthcare Series [database on the internet]. Greenwood Village (CO): Truven Health Analytics. Updated periodically; [cited 2022 Sep 6]. Available from: <http://www.thomsonhc.com/>.

Review History

01/11/23 - Reviewed and created for Jan P&T; matched MH UPPL. Created criteria to be in compliance with Masshealth unified formulary requirements. Effective 4/1/23

04/10/23 – Reviewed and updated for P&T. Zilretta will only be available on MB with PA. Effective 5/6/24

05/15/25 – Reviewed and created for P&T. Updated formatting and references. Effective 6/1/25